Polyrizon Ltd. has achieved a significant milestone by successfully completing the enrollment of all 120 patients in its U.S. clinical study for NASARIX, a proprietary nasal hydrogel designed to protect against airborne allergens. This development is crucial for the company as it moves closer to obtaining clinical data that could advance its innovative allergy treatment.

Founded in Raanana, Israel, Polyrizon operates within the surgical and medical instruments and apparatus industry, specifically focusing on the development of intranasal hydrogels. The company trades on the Nasdaq under the ticker symbol PLRZ. Recent filings include a Form 6-K on October 27, 2026, detailing this latest achievement.

The recent filing states, "The study has reached its planned enrollment target, with 120 participants randomized across five clinical research sites in the United States." This statement underscores the company's commitment to advancing its clinical research and development efforts.

This successful enrollment is expected to impact various stakeholders, including patients suffering from allergic rhinitis, healthcare providers, and investors interested in the biotechnology sector. As Polyrizon continues its clinical study, the results could provide valuable insights into the effectiveness of NASARIX compared to standard saline treatments.

Looking ahead, the company will focus on completing the remaining study activities and aims to advance towards the clinical data readout. The filing does not specify any upcoming meetings or further filings related to this study.